首页 > 市场调查报告书 > 製药

抗血小板药物市场：按药物类别、给药方法、应用、地区 - 规模、份额、前景、机会分析，2022-2030

市场调查报告书

商品编码

1110234

抗血小板药物市场：按药物类别、给药方法、应用、地区 - 规模、份额、前景、机会分析，2022-2030

Antiplatelet Drugs Market, by Drug Class, by Mode of Administration, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月28日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

简介目录

为心脏病发作的人开具抗血小板药物，这些药物有助于防止心脏病发作再次发生。抗血小板药物包括阿司匹林、氯□格雷、普拉格雷和替格瑞洛。除非存在超敏反应，否则建议所有急性冠状动脉综合征 (ACS) 患者使用阿司匹林。它与口服抗血小板药物如氯□格雷、普拉格雷和替格瑞洛一起开处方。普拉格雷被开给患有 ACS 或接受经皮冠状动脉介入治疗 (PCI) 的患者。氯□格雷和替格瑞洛有助于预防成人 ACS 患者和接受冠状动脉旁路移植术 (CABG) 或 PCI 治疗的患者的动脉粥样硬化血栓事件。

市场动态

肥胖、糖尿病和心血管疾病 (CVD) 等慢性病不断增加，增加了心脏病发作的风险，从而推动了对抗血小板药物的需求。例如，根据美国糖尿病协会的数据，2019 年，3730 万美国公民，或 11.3% 的人口患有糖尿病。在 3730 万成年人中，约有 190 万美国公民患有 1 型糖尿病，其中包括约 244,000 名儿童和青少年。在 3730 万成年人中，有 2870 万人被诊断患有糖尿病，850 万人未确诊。 2019 年，9600 万 18 岁及以上的美国公民处于糖尿病前期。每年有 140 万美国人被诊断出患有糖尿病。美国疾病控制与预防中心报告称，2017-2018 年，心脏病每年给美国造成的损失约为 2290 亿美元。这包括医疗服务、药品和因死亡而导致的生产力损失等费用。根据疾病控制和预防中心的数据，2019 年美国约有 2010 万 20 岁及以上的成年人患有冠状动脉疾病。

本研究的主要特点

本报告对全球抗血小板药物市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%) 的增长。
解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
基于公司亮点、产品组合、关键亮点、财务业绩和战略等参数的全球抗血小板药物市场主要参与者的概况。
本研究涵盖的主要公司包括 AstraZeneca Plc、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Daiichi Sankyo, Inc.、Eli Lilly and Company、Merck & Co., Inc.、Otsuka Pharmaceutical Company, Ltd.。、赛诺菲和医药公司
本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
《全球抗血小板药物市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
通过用于分析全球抗血小板药物市场的各种战略矩阵促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第2章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场快照：按药物类别
- 市场快照：按剂型
- 市场快照：按应用
- 市场概况：按地区划分
连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 驱动程序
- 约束因素
- 市场机会
影响分析
市场趋势
近期趋势
收购和合作方案
技术概述
监管场景
定价分析
流行病学分析
波特五力

第 4 章全球抗血小板药物市场 - 冠状病毒 (COVID-19) 大流行的影响

整体影响
政府举措
COVID-19 对市场的影响

第 5 章全球抗血小板药物市场，按药物类别，2017-2030 年

不可逆的环氧合□ (COX) 抑製剂
二磷酸腺甘 (ADP) 受体抑製剂
糖蛋白 IIB/IIIA 抑製剂
腺甘再摄取抑製剂
血栓素抑製剂和磷酸二酯□抑製剂

第 6 章全球抗血小板药物市场，按剂型，2017-2030 年

口服给药
静脉给药

第 7 章全球抗血小板市场：按应用，2017-2030 年

血管成形术
动脉血栓栓塞
心肌梗塞
经皮冠状动脉介入治疗
其他

第 8 章全球抗血小板药物市场，按地区，2017-2030 年

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海合会
以色列
其他中东地区
非洲
北非
中非
南非

第 9 章竞争格局

热图分析
公司简介
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

第10章章节

参考文献
调查手法

简介目录

Product Code: CMI2190

Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Market Dynamics

Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.

Key features of the study:

This report provides an in-depth analysis of the global antiplatelet drugs market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiplatelet drugs market

Detailed Segmentation:

Global Antiplatelet Drugs Market , By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Global Antiplatelet Drugs Market , By Mode of Administration:
- Oral
- Intravenous
Global Antiplatelet Drugs Market , By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
Global Antiplatelet Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- AstraZeneca Plc*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
Epidemiology Analysis
PORTER'S Five Forces

4. Global Antiplatelet Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Antiplatelet Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Irreversible Cyclooxygenase (COX) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Adenosine Diphosphate (ADP) Receptor Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Glycoprotein IIB/IIIA Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Adenosine Reuptake Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Antiplatelet Drugs Market, By Mode of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Antiplatelet Drugs Market, By Application, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Angioplasty
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Arterial Thrombosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Myocardial Infarction
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Percutaneous Coronary Interventions
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Antiplatelet Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mode of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa